论文部分内容阅读
目的:探讨加味二陈汤对痰湿型2型糖尿病患者外周血T淋巴细胞亚群的影响.方法:将130例痰湿型2型糖尿病患者随机分为对照组和治疗组各65例.所有患者均接受运动疗法、饮食干预等基础治疗,对照组在此基础上采用瑞格列奈治疗,治疗组在基础治疗基础上采用加味二陈汤治疗.比较两组治疗前后临床症状、糖化血红蛋白(HbA1c)、空腹血糖(FPG)、餐后2h血糖(2 hPG)、外周血T细胞亚群Th1、Th2、Th1/Th2比值变化情况及不良反应发生情况,并评价两组临床疗效.结果:与治疗前比较,两组治疗后中医证候积分、FPG、2hPG、HbA1c、Th1、Th1/Th2比值均下降(P＜0.05),而Th2上升(R0.05);治疗后两组比较,治疗组FPG、2hPG、HbA1c、Th1、Th1/Th2比值低于对照组(P＜0.05),而Th2高于对照组(P＜0.05);治疗组总有效率为92.3％,对照组总有效率为73.9％;治疗组不良反应发生率为1.5％,对照组不良反应发生率为12.3％.两组总有效率、不良反应发生率比较,差异均有统计学意义(P＜0.05).结论:采用加味二陈汤对痰湿型2型糖尿病患者进行治疗,可显著提高临床疗效,缓解临床症状,降低血糖水平,改善外周血T淋巴细胞亚群的紊乱情况,且不良反应少.“,”Objective:To investigate the effect of modified Erchen decoction (加味二陈汤,MECD) on peripheral blood T lymphocyte subsets in patients with phlegm-dampness syndrome of type 2 diabetes mellitus (T2DM).Methods:The 130 patients with phlegm-dampness syndrome of T2DM treated in our hospital from August 2015 to July 2016 were divided into two groups by registration order,odd numbers were included into control group (n=65) and even numbers were included into research group (n=65).All the patients received basic treatment with exercise therapy and diet intervention,and on this basis,control group took repaglinide and research group took MECD.The changes of clinical symptoms,blood glucose level [glycosylated hemoglobin (HbA1c),fasting plasma glucose (FPG),2 hours postprandial blood glucose (2 h PG)],peripheral blood T lymphocyte subsets of Th1,Th2,Th1/Th2 ratio,adverse reactions in two groups before and after treatment were compared,the clinical efficacy and safety of two groups were evaluated.Results:Compared with before treatment,the TCM symptom score,FPG,2 h PG,HbA1c,Th1,Th1/Th2 ratio of two groups decreased after treatment,but Th2 increased,and above indexes of research group were better than control group after treatment (P＜0.05);The total effective rate,incidence of adverse reactions in research group were 92.3％ (60/65),1.5％ (1/65),which were better than control group [73.9％(48/65),12.3％(8/65)] (P＜0.05).Conclusion:MECD for peripheral blood T lymphocyte subsets in patients with phlegm-dampness syndrome of T2DM can significantly increase clinical efficacy,relieve clinical symptoms,decrease blood glucose level,improve disorders of peripheral blood T lymphocyte subsets and have less adverse reactions.